Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series

• 主要な著者: Juliana Park (著者), Sophia Archuleta (著者), May-Lin Helen Oh (著者), Lynette Pei-Chi Shek (著者), Jing Jin (著者), Matthew Bonaparte (著者), Carina Frago (著者), Alain Bouckenooghe (著者)
• フォーマット: 図書
• 出版事項: Taylor & Francis Group, 2020-03-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in Asia and Latin America. In this study, CYD63 (NCT02824198), participants aged 9-45 years at first vaccination, and who had r...